Early switching between ADHD medications

2021 ◽  
Author(s):  
Steve Chaplin
Keyword(s):  
Adhd Medications

Efficacy and tolerability of ADHD medications in a clinical practice

2015 ◽  
Vol 06 (01) ◽  
pp. 005-010 ◽  
Author(s):  
Jill Miller-Horn ◽  
Joseph Kaleyias ◽  
Ignacio Valencia ◽  
Joseph Melvin ◽  
Divya Khurana ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Adhd Medications

Recent Trends in the Prescribing of ADHD Medications in Canadian Primary Care

2017 ◽  
Vol 24 (2) ◽  
pp. 301-308 ◽  
Author(s):  
Rachael Morkem ◽  
Scott Patten ◽  
John Queenan ◽  
David Barber
Keyword(s):  
Primary Care ◽  
Age Groups ◽  
Fold Increase ◽  
Population Based ◽  
Adhd Medication ◽  
Fourfold Increase ◽  
School Aged Children ◽  
Medication Prescribing ◽  
And Gender ◽  
Adhd Medications

Objective: The aim of this study was to describe the prevalence and incidence of ADHD medication prescribing, by age and gender, from 2005 to 2015 in Canadian primary care. Method: A population-based retrospective cohort study was conducted to evaluate the prescribing of ADHD medications between 2005 and 2015 using electronic medical record data. Yearly prevalence and incidence of ADHD medication prescribing were calculated for preschoolers (up to 5 years old), school-aged children (6-17 years old), and adults (18-65 years old) along with a description of the types of ADHD medications prescribed between 2005 and 2015. Results: Between 2005 and 2015, there was a 2.6-fold increase in the prevalence of ADHD medication prescribing to preschoolers, a 2.5-fold increase in school-aged children, and a fourfold increase in adults. There was a corresponding rise in incidence of prescribing although this rise was moderate and estimates were much lower compared with prevalence. The most commonly prescribed medication was Methylphenidate (65.0% of all ADHD medications prescribed). Conclusion: Although the prevalence of ADHD has remained stable over time, this study found an increase in the prescribing of ADHD medications in all age groups between 2005 and 2015. Incidence of new prescriptions was small relative to prevalence, suggesting that longer term treatments are being adopted.

Neurobiology and Genetics of ADHD in Adults

CNS Spectrums ◽  
2008 ◽  
Vol 13 (S13) ◽  
pp. 5-7 ◽  
Author(s):  
Thomas J. Spencer
Keyword(s):  
Adult Adhd ◽  
Extended Release ◽  
Treatment Strategies ◽  
Stimulant Use ◽  
Hyperactivity Disorder ◽  
Adhd Treatment ◽  
Norepinephrine Reuptake Inhibitor ◽  
Adults And Children ◽  
Core Symptoms ◽  
Adhd Medications

AbstractTreatment of attention-deficit/hyperactivity disorder (ADHD) may positively impact the neurobiology of adult patients with ADHD. Treatment may also minimize impairment from core symptoms and may alter the course of co-morbid disorders such as depression and substance use disorder. However, much of the information on stimulant use in adult ADHD comes from studies conducted in children, and it remains unclear whether there is a difference between children and adults when it comes to the side effects and tolerability of ADHD treatments. It is known that clinical presentation differs between adults and children, with adults demonstrating a higher percentage of mood disorders. Current treatments for adult ADHD include psychosocial therapies and pharmacologic therapies, the latter of which include the stimulants d-methylphenidate extended release (XR), OROS methylphenidate, lisdexamfetamine, and mixed amphetamine salts XR; and the nonstimulant atomoxetine, a selective norepinephrine reuptake inhibitor. There is need for additional study of treatment strategies for adult ADHD. Although all classes of ADHD medications are approved in adults, there are fewer approved formulations for adults than for children. Efficacy in adults is more subjective than in children, which may affect how efficacy rates for adult treatments are calculated. Adults also present a greater diversion risk than children. In addition, there are several new and emerging medication treatments worth considering.This Expert Roundtable Supplement represents part 2 of a 3-part supplement series on adult ADHD led by Lenard A. Adler, MD. In this activity, Thomas J. Spencer, MD, discusses the neurobiology and genetics of adult ADHD; Mark A. Stein, PhD, discusses stimulant therapy; and Jeffrey H. Newcorn, MD, reviews nonstimulants and psychosocial treatments.

The Misuse and Diversion of Prescribed ADHD Medications by College Students

2009 ◽  
Vol 13 (2) ◽  
pp. 144-153 ◽  
Author(s):  
David L. Rabiner ◽  
Arthur D. Anastopoulos ◽  
E. Jane Costello ◽  
Rick H. Hoyle ◽  
Sean Esteban McCabe ◽  
...  
Keyword(s):  
College Students ◽  
Adhd Medications

scholarly journals Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review

2018 ◽  
Vol 104 (4) ◽  
pp. 619-637 ◽  
Author(s):  
Tanya E. Froehlich ◽  
Jason Fogler ◽  
William J. Barbaresi ◽  
Nada A. Elsayed ◽  
Steven W. Evans ◽  
...  
Keyword(s):  
Systematic Review ◽  
Reading Disorders ◽  
Adhd Medications

Changes in authenticity

2018 ◽  
pp. 312-323
Author(s):  
Erez C. Miller ◽  
Amos Fleischmann
Keyword(s):  
Social Media ◽  
Medical Condition ◽  
Medication Use ◽  
Sense Of Control ◽  
Online Forums ◽  
Hyperactivity Disorder ◽  
Internet Forums ◽  
The Cost ◽  
Adhd Medications ◽  
Medical Perspective

The use of medications for attention deficit hyperactivity disorder (ADHD) has been strongly debated because medications may alter the individual’s sense of authenticity. This chapter examines online forums that include young people’s experiences with ADHD medications, their sense of control over medication use, and the drugs’ effects on their sense of authenticity. It discusses the analysis of four Internet forums dedicated to ADHD issues using an ethnographic-discursive approach, and demonstrates that the results suggest there are two types of competing narratives—those of the young people, who express doubts about taking medications due to their effect on various psychological characteristics and especially on their sense of authenticity, and those of professionals, who uphold the medical perspective that regardless of the medications’ effects they are still the best option for treating ADHD. It covers how the clash between these two competing narratives resonates a more general struggle of people with disabilities for their rights. Finally, it discusses how social media echoes the struggle between individuals with disabilities and the establishment’s view of ADHD as a medical condition which should be treated accordingly, even at the cost of losing the individual’s authenticity.

scholarly journals Objective Evaluation of Therapeutic Effects of ADHD Medication Using a Smart Watch: A Pilot Study

2020 ◽  
Vol 10 (17) ◽  
pp. 5946
Author(s):  
Chen-Sen Ouyang ◽  
Rei-Cheng Yang ◽  
Ching-Tai Chiang ◽  
Rong-Ching Wu ◽  
Lung-Chang Lin
Keyword(s):  
Rating Scale ◽  
Objective Evaluation ◽  
Therapeutic Effects ◽  
Adhd Medication ◽  
Objective Method ◽  
Analog Scale ◽  
Hyperactivity Disorder ◽  
Smart Watch ◽  
Before And After ◽  
Adhd Medications

Attention-deficit hyperactivity disorder (ADHD) is the most common neurobehavioral disorder in schoolchildren. Several methods are used to evaluate ADHD therapeutic effects, including the Swanson, Nolan, and Pelham (SNAP) questionnaire, the Vanderbilt ADHD Diagnostic Rating Scale, and the visual analog scale. However, these scales are subjective. In this study, we employed an objective method to evaluate the aforementioned therapeutic effects. Ten patients (nine boys and one girl) with ADHD were enrolled. An accelerometer was embedded in a smart watch to record the movements of patients with ADHD. The variance values of the accelerometer before and after one month of medication (methylphenidate) use were compared. The results demonstrated that the variance values along the y- and z-axes of the accelerometers significantly decreased after one month of methylphenidate use. Before and after one month of methylphenidate use, the variance values were 4.4227 ± 2.1723 and 2.3214 ± 0.6475 (p = 0.0119) on the y-axis, and 4.0933 ± 1.5720 and 2.4091 ± 0.8141 (p = 0.0140) on the z-axis, respectively. In addition, the correlation was moderate-to-strong between the SNAP hyperactivity subscale and variance along the y-axis. Thus, a smart watch with an accelerometer inside is potentially an objective and useful method for evaluating the therapeutic effects of ADHD medications.

Sign in / Sign up

Export Citation Format

Share Document